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Cell based assayAntibodies labeled with small molecules such as ﬂuorophore, biotin or drugs play an important role in various
areas of biological research, drug discovery and diagnostics. However, themajority of current methods for label-
ing antibodies is solution-based and has several limitations including the need for puriﬁed antibodies at high con-
centrations and multiple buffer exchange steps. In this study, a method (on-bead conjugation) is described that
addresses these limitations by combining antibody puriﬁcation and conjugation in a singleworkﬂow. Thismeth-
od uses high capacity-magnetic Protein A or Protein G beads to capture antibodies directly from cell media
followed by conjugation with small molecules and elution of conjugated antibodies from the beads. High-
capacity magnetic antibody capture beads are key to this method and were developed by combining porous
and hydrophilic cellulose beads with oriented immobilization of Protein A and Protein G using HaloTag technol-
ogy. With a variety of ﬂuorophores it is shown that the on-bead conjugation method is compatible with both
thiol- and amine-based chemistry. This method enables simple and rapid processing of multiple samples in par-
allel with high-efﬁciency antibody recovery. It is further shown that recovered antibodies are functional and
compatible with downstream applications.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Labeled antibodies are cornerstone in biological research and diag-
nostic testing with applications in immunodetection, immunoassays,
immunohistochemistry, cell imaging and many others. An indication
of the usefulness of the labeled antibodies is the variety of small mole-
cules that have been conjugated to the antibodies including biotin, ﬂuo-
rescent dyes, proteins, nanoparticles and radioactive molecules for a
variety of applications (Silverstein, 2004). More recently, labeled anti-
bodies are also ﬁnding therapeutic applications, where drug molecules
are attached to antibodies, resulting in improved disease treatments
(Drachman and Senter, 2013; Panowksi et al., 2014). The terms labeling
and conjugation are used interchangeably throughout the text.
Alongwith the increasing use of labeled antibodies as reagents there is
a growing need for proper validation of the antibodies and related
reagents to reduce the chances of false results (Bradbury and Pluckthun,
2015; Colwill, 2011). Although simple in concept, making validated la-
beled antibodies requires a lengthy process of generating antibodies, op-
timizing labeling chemistry and screening labeled antibodies for intended
applications. Thus there is a desire for easy and robust methods that will
allow multiple antibodies to be labeled and screened in relevant assays,
preferably during the early stages of the antibody development process.. This is an open access article underCurrently, the two most common antibody labeling methods use
amine and thiol groups present at lysine and cysteine amino acids on
the antibody (Flygare et al., 2013). These methods are solution-based
multistep reactions involving several incubations and buffer exchange
steps hence limiting the throughput of the method. In addition,
solution-based conjugation requires puriﬁed antibody at relatively
high concentrations (N1.0 mg/ml) thus limiting its utility during the
early monoclonal screening stage where sample volume is limited and
antibody titers are low (50 μg/ml). To alleviate some of these limita-
tions, on-bead labeling methods were developed (Lyon et al., 2012;
Strachan et al., 2004), where antibody is captured onto the non-
magnetic bead surface followed by labeling and elution to recover la-
beled antibody. Thesemethods have the advantage of combining puriﬁ-
cation and labeling in a single workﬂow but are done in a batch or
column format, which limits the number of samples. More recently a
magnetic bead-based antibody labeling methodology was developed
to label up to twelve polyclonal antibodies in parallel (Dezfouli et al.,
2014). The method is an improvement over non-magnetic bead-based
labelingmethods and shows nanogram-scale labeling of polyclonal rab-
bit antibodies.
To further broaden the utility of magnetic bead-based antibody la-
beling methods to include sample types such as hybridoma cell media
containing various concentrations and isotypes of antibodies, high-
capacity antibody-binding magnetic beads were developed, and a sim-
ple workﬂow was optimized for on-bead antibody puriﬁcation andthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Schematic of magnetic on-bead antibody conjugation using (A) thiols on cysteine residues and (B) amines on lysine residues.
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based chemistry and offers the ﬂexibility of handling multiple samples
in a manual or automated fashion. A key advantage of using high-
capacity magnetic beads in this workﬂow is that a very small amount
of beads is sufﬁcient for efﬁcient capture of antibody from dilute cell
media. This results in concentrated antibody on the bead and leads to ef-
ﬁcient conjugation reactions. In addition, the low amount of beads
means that the conjugated antibodies can be eluted in a small volume
resulting in a fairly high concentration amenable for direct use in down-
stream applications. Lastly, in this method, removal of unincorporated
labels is accomplished by simple washing steps while antibody remains
bound to the beads, eliminating the need for buffer exchange.
High-capacity antibody-binding magnetic beads were key to the
method and developed by combining two novel approaches. First was
the selection of porous magnetic cellulose beads (30 μm–80 μm) be-
cause they offer high surface area and the hydrophilic cellulose shows
low non-speciﬁc protein binding. Second was the choice of HaloTag
technology for the covalent and oriented immobilization of Protein A
or Protein G (Fig. 2), the two commonly used afﬁnity ligands for capture
and puriﬁcation of antibodies. HaloTag is a 34 kDa protein fusion tag
that forms a speciﬁc and covalent bond with synthetic HaloTag ligands
and has been used previously to orient the protein of interest on a vari-
ety of surfaces (Urh and Rosenberg, 2012; Los et al., 2008). The choice of
oriented immobilization of Protein A and Protein G instead of random
attachment chemistry using lysines was driven by literature reporting
better protein functionality using oriented immobilization (WeinrichFig. 2. Schematic showing oriented and covalent immobilization of Halet al., 2010; Colombo et al., 2012; Ha et al., 2007; Jung et al., 2007). By
combining porous cellulose beads and oriented protein attachment
chemistry, magnetic Protein A and magnetic Protein G beads were de-
veloped. These beads have a high antibody-binding capacity similar to
that of many commercial non-magnetic beads (~25 mg Human IgG/
ml of beads).
High-capacity antibody-binding magnetic beads were subsequently
used to optimizemethods for on-bead labeling of antibodies. Using sev-
eral ﬂuorescent dyes it was demonstrated that on-bead labeling of anti-
bodies is compatible with amine- and thiol-based chemistries as well as
with a variety of mouse and human antibody isotypes either puriﬁed or
present in cell media. Finally, data is presented to show that antibodies
with various dye-to-antibody ratios (DAR) can be made using this
method, and these conjugated antibodies maintain their functionality
as demonstrated by several downstream applications.
2. Materials and methods
2.1. Development of high-capacity magnetic Protein G and magnetic Pro-
tein A beads
2.1.1. Protein expression and puriﬁcation
To generate Protein G-HaloTag fusion, the coding sequence for three
domains of Protein G that bind the IgG Fc domain (from CAA27638
Streptococcus (Group G Strain G148)) were synthesized with an N-
terminal (HQ)5 tag and a C-terminal HaloTag. For making Protein A-oTag fusion of Protein G or Protein A on magnetic cellulose beads.
97N. Nath et al. / Journal of Immunological Methods 426 (2015) 95–103HaloTag protein, coding sequence from ﬁve domains of Protein A that
bind the Fc section of IgG (GenBank: EFB98015.1) were synthesized
with an N-terminal (HQ)5 tag and a C-terminal HaloTag. Sequences
were ﬂanked by Sgf I and Pme I sites and transferred to the pF1K T7
Flexi Vector (Accession Number AY753577). The resulting vector was
transformed into Single Step (KRX) Competent Cells (Promega). Pro-
teins were expressed using the late auto-induction conditions (0.15%
glucose/0.2% rhamose) in LBmedia at 25 °C for 18–24 h. Cells were har-
vested, lysed and proteins puriﬁed through anHQ tag usingHisLink Pro-
tein Puriﬁcation Resin (Promega) following themanufacturer's protocol
followed by a Q-sepharose column. Protein was quantitated using the
Bradford assay, and purity was checked using SDS-PAGE gel analysis.
2.1.2. Development of magnetic Protein G and Protein A beads
Magnetic Protein G and Protein A beads were made by incubating
puriﬁed Protein G-HaloTag and Protein A-HaloTag, respectively, with
Magne HaloTag Beads (Promega). Magne HaloTag Beads are magnetic
cellulose beads activated with HaloTag Ligands and can be used for
various applications including HaloTag protein puriﬁcation and
protein:protein interaction studies (Banks et al., 2014; Saul et al.,
2014). To optimize conditions for Protein A-HaloTag and Protein G-
HaloTag conjugation, Magnetic HaloTag Beads were pipetted into
1.5 ml microcentrifuge tubes, washed with HEPES buffer (pH 7.2) and
incubated with different amounts of Protein A-HaloTag or Protein G-
HaloTag inHEPES buffer. The ratio of sample volume to settled bead vol-
ume was 4:1, and binding was done at room temperature for 2 h with
constant end-over-end rotation. Following incubation, the amount of
protein in the ﬂow-through was determined using absorbance at
280 nm and used to calculate the amount of protein captured on the
Magnetic HaloTag Beads. Beads were washed three times with HEPES
buffer and stored in 20% ethanol as 20% slurry at 4 °C. For various wash-
ing steps described in this and the following sections, samples with
magnetic beads were placed in the magnetic stand (MagneSphere®
Technology Magnetic Separation Stand (twelve-position; Promega)),
which pulls the beads to one side and allows solution to be easily re-
moved using a pipette without any loss of magnetic beads.
2.1.3. Antibody binding capacity of magnetic Protein G and Protein A beads
Maximum binding capacities of magnetic Protein A and Protein G
beads were determined by incubating 10 μl (bead volumes mentioned
in this paper refer to the settled volume) of each bead type with
400 μg of puriﬁed polyclonal Human IgG (Sigma or Rockland Immuno-
chemicals) in 200 μl of PBS for 30–60 min. After washing (three times
with 200 μl of PBS), bead bound-antibody was eluted twice with 50 μl
of elution buffer (10 mM glycine-HCl buffer, pH 2.2–2.7) and immedi-
ately neutralized with 10 μl of neutralization buffer (2 M Tris buffer,
pH 7.5). To test the binding capacity of various isotypes of antibodies
under conditions similar to that in the early hybridoma screening
stage, puriﬁed antibodies from different species (Sigma or Rockland Im-
munochemicals) were spiked in PBS at 50 μg/ml, and 1.0 ml samples
were incubated with 10 μl of either magnetic Protein A or Protein G
beads for 30–60 min. After washing, antibodies were eluted twice
with 50 μl of elution buffer and immediately neutralized with 10 μl of
neutralization buffer. The amount of antibody recovered was calculated
using absorbance at 280 nm.
2.2. Antibody-small molecule conjugation on magnetic Protein G and Pro-
tein A beads (on-bead conjugation)
Uses of optimized high-capacity magnetic Protein A (Magne Protein
A Beads from Promega) and Protein G beads (Magne Protein G Beads
from Promega) for on-bead puriﬁcation and conjugation of antibodies
were shownusing severalﬂuorescent dyes. Both the amine and thiol re-
actions were tested, and several cell media samples expressing various
isotypes of mouse antibodies were used to demonstrate the utility of
the workﬂow.2.2.1. Puriﬁcation and conjugation ofmouse antibodies with AlexaFluor 532
using amine reaction
Combined on-bead puriﬁcation and conjugation of mouse antibod-
ies using amine chemistry was performed with three different cell
media samples containing mIgG1, mIgG2a and mIgG2b (Rockland Im-
munochemicals) at 50–100 μg/ml. One milliliter samples were incubat-
ed for 60 min with 10 μl of magnetic Protein G beads with constant
mixing. After washing twicewith 200 μl of PBS to remove nonspeciﬁcal-
ly bound proteins, beads were incubated for 1 h with 25 μg (~35 μmol)
of amine-reactive AlexaFluor 532 Dye (Life Technologies) in 50 μl of
10 mM phosphate buffer (PB) (pH 8.0). Beads were again washed
three timeswith 10mMPB (pH7.0), and labeled antibodieswere eluted
twice using 50 μl of elution buffer and immediately neutralized by 10 μl
of neutralization buffer. Two aliquots were combined before quantitat-
ing antibody concentration and DAR as suggested by the dye provider.
To determine if various chemical conjugation steps led to any loss of an-
tibody, a simple puriﬁcation of antibody from three cell media samples
was also performed, and the antibody recovered was compared to the
antibody recovered after conjugation. The amount of puriﬁed antibody
was calculated using absorbance at 280 nm, and purity was checked
using SDS-PAGE gel analysis.
2.2.2. Puriﬁcation and conjugation ofmouse antibodies with AlexaFluor 532
using thiol reaction
Combined on-bead puriﬁcation and conjugation using thiol chemis-
try was performed using the same three samples used in the previous
section. One milliliter samples were incubated for 60 min with 10 μl of
magnetic Protein G beads with constant mixing. After washing three
times with 10 mM PB (pH 7.0) to remove nonspeciﬁcally bound pro-
teins, bead-bound antibodies were incubated for 60 min with 2.5 mM
DTT in PBE (10 mMPBwith 1 mM EDTA (pH 7.0)) to selectively reduce
inter-chain disulﬁde bonds. Following three washings with 200 μl of
PBE to remove DTT, reduced antibodies on the beads were reacted for
1 hwith ~35 μmol ofmaleimide-activatedAlexaFluor 532 (Life Technol-
ogies) in 50 μl of PBE. Beads were washed three times with PBE, and la-
beled antibodies were eluted and neutralized as before. A separate
puriﬁcation step of the three antibodies was also performed to compare
the recoveries with and without the conjugation step. Antibody recov-
ery, purity and DAR were calculated as described in the previous
section.
2.2.3. Puriﬁcation and conjugation of mIgG2a with AlexaFluor 532,
AlexaFluor 647 and Fluorescein using thiol reaction
Three different maleimide dyes, AlexaFluor 532, AlexaFluor 647 and
Fluorescein, were used to label mIgG2a. To simulate cell media samples
with high antibody concentration, cell media containing mIgG2a was
concentrated about two- to threefold (Rockland Immunochemicals).
The conjugation reaction was performed as described in the previous
section using thiol chemistry with the following changes; to accommo-
date the higher amount of antibody, conjugation was performed using
20 μl of both magnetic Protein A and Protein G beads, and the amount
of dye used was about 70 μmol in 100 μl of buffer. Elution and neutrali-
zation buffer amounts were doubled.
2.3. Antibody functional assays
To demonstrate that antibody conjugated using the on-bead conju-
gation method retains its functional activity we labeled an anti-HER2
antibody (Trastuzumab) with AlexaFluor 647 and tested it in cell-
based assays.
2.3.1. Conjugation of Trastuzumab with AlexaFluor 647 using amine
reaction
Four hundredmicrograms of puriﬁed Trastuzumabwas captured on
30 μl of magnetic Protein G beads and reacted with amine-reactive
AlexaFluor 647 dye as described before. Conjugated Trastuzumab was
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neutralization buffer.
2.3.2. Cell-based ELISA of Trastuzumab
SKBR3 cells overexpressing HER2 and MDA-MB-231 cells with
very low expression of HER2 were plated at 15,000 cells per well
in a 96-well polystyrene plate and grown to conﬂuence by over-
night incubation at 37 °C. Cells were ﬁxed using 4% paraformalde-
hyde and incubated with various dilutions of Trastuzumab or
Trastuzumab labeled with AlexaFluor 647 for 1 h. Dilutions were
made in PBS containing 10 mg/ml BSA (PBSB). After washing
with PBS containing 0.05% Tween 20 (PBST), plates were incubated
for 1 h with Anti-Human-IgG (H + L)-HRP (horseradish peroxi-
dase) Conjugate (Promega) diluted 1:5000-fold in PBSB. After
washing with PBST, TMB (3,3′, 5,5′-tetramethylbenzidine)
(Promega) was used as the HRP substrate. The colorimetric reac-
tion was stopped by adding 1 N HCl and plates were read at
595 nm.
2.3.3. Cell-based internalization studies of Trastuzumab
SKBR3 cells were plated at 30,000 cells perwell in 8-well chambered
cover glass and incubated for 48 h. Trastuzumab or Human IgG labeled
with ﬂuorescent dyes was added at 30 nM in complete media and incu-
bated for 24 h. Cellswerewashedwith completemedia, and plateswere
imaged on a Nikon ConfocalMicroscope using the appropriate ﬁlter sets
for each dye.MDA-MB-231 cells with very low expression of HER2were
used as negative-control cells.
3. Results
3.1. Development of high-capacity magnetic Protein G and Protein A beads
Oriented and covalent attachment of Protein A and Protein G on a
high-surface area porous magnetic bead was critical for development
of high-capacity antibody-binding beads. The approach was to use
HaloTag fusions of Protein A and Protein G for covalent and oriented at-
tachment to a porous magnetic cellulose bead activated with the
HaloTag Ligand. HaloTag fusions of Protein A and Protein G expressed
very well in Escherichia coli and were puriﬁed using His-Tag beads
followed by a Q column to obtain proteins at N95% purity. Incubation
of puriﬁed HaloTag fusion proteins with Magne HaloTag Beads allowed
speciﬁc, covalent and oriented capture of Protein A and Protein G. Un-
like other afﬁnity tags where binding is reversible and equilibrium-
based, the covalent binding between HaloTag and its ligand allows efﬁ-
cient and quantitative capture on the magnetic beads. This advantage is
important as it allowed us to exactly tune the amount of protein at the
surface simply by incubating the beads with increasing amounts of the
HaloTag fusion as shown for Protein G-HaloTag in Fig. 3A. Subsequently,
these magnetic beads charged with varying amounts of Protein G-
HaloTag were used for human IgG puriﬁcation (Fig. 3B). MaximumFig. 3. (A) Capture efﬁciency of Protein G-HaloTag on Magne HaloTag Beads. (B) Antibody re
readings.human IgG capture of about 30 mg/ml of bead (200 nmol assuming
m.wt = 150 kDa) was reached at around 10 mg of Protein G-
HaloTag/ml of bead (128 nmol assuming m.wt = 58 kDa) giving a
ratio of about 1.2 antibody molecules per molecule of Protein G.
This ratio is similar to that reported in the literature for solution-
phase reactions (Lund et al., 2011) between Protein G and antibody,
and it indicates that oriented attachment of proteins maintains the
functionality of the protein. Almost quantitative binding to magnetic
HaloTag beads was again seen with the HaloTag fusion of Protein A.
The peak antibody recovery of about 21 mg of Human IgG
(140 nmol) was achieved at around 5.5 mg of Protein A-HaloTag on
the bead (77 nmol assuming m.wt = 70 kDa), and antibody recovery
actually decreased at higher loading of Protein A probably due to ste-
ric inhibition (data not shown).
Optimized magnetic Protein G beads and Protein A beads were sub-
sequently tested for capture and recovery of various isotypes of mouse
and human IgG from a 1.0 ml sample spiked with 50 μg/ml of antibody.
This concentration is typical of cell media samples during the early an-
tibody discovery phase. Recoveries of various antibodies ranged from
60 to 80% of the input amount (Table 1).
3.2. Puriﬁcation and on-bead conjugation of mouse antibodies using amine
reaction
To test the ability of high-capacitymagnetic Protein G and Protein
A beads to capture antibodies from cell media followed by on-bead
chemical conjugation, antibody conjugation was tested ﬁrst through
amines on the lysine residues of the antibodies. These sites are the
most common reactive groups on antibodies and are frequently
used for conjugation with dyes, drug molecules and peptides.
AlexaFluor 532 was used with an amine-reactive succinimidyl ester
(AlexaFluor 532-SE) to label various mouse antibody isotypes
(mIgG1, mIgG2a and mIgG2b) present in the cell media at a typical
expression level of ~50–100 μg/ml (0.33–0.66 nmol/ml).
Tenmicroliters of magnetic Protein G beads was used to capture an-
tibodies from the samples, washed to remove any non-speciﬁcally
bound proteins and then incubated with 25 μg (35 nmol) of AlexaFluor
532-SE dye in 50 μl of 10 mM PB (pH 8.0). Following another washing
step to remove excess free dye, conjugated antibodies were eluted
from thebeads using a quick low-pH (pH2.2)wash, and eluted antibod-
ies were neutralized immediately. Efﬁciency of labeling was calculated
using DAR as suggested by the manufacturer. Results showed a DAR of
4.0–5.0 (Table 2), which is in the range of 2–4 labels per antibody and
has been shown to be optimal for maintaining antibody activity (Vira
et al., 2010). In fact, two antibody drug conjugates (ADCs) approved
by the FDA contain an average of 3.5 drugs per antibody (Drachman
and Senter, 2013; Panowksi et al., 2014). It is worth mentioning that
AlexaFluor 532-SE also reacts with lysines on the Protein G-HaloTag,
but in the presence of a large excess of reactive dye, it was possible to
consistently label antibodies with high DARs.covery as a function of Protein G-HaloTag on the bead. Each point is the average of two
Table 1
Antibody recovery using magnetic Protein G and Protein A beads.
Amount of IgG puriﬁed from 50 μg input sample (μg)
Species Isotype Magnetic Protein G beads Magnetic Protein A beads
Human IgA 0.4 ± 0.3 4.8 ± 2.1
IgG1 39.4 ± 1.8 35.2 ± 1.9
IgG2 32.6 ± 0.7 34.4 ± 0.7
IgG3 37.6 ± 2.4 0
IgG4 38.0 ± 8.6 28.8 ± 2.75
IgM 0 8.2 ± 0.7
Mouse IgG1 30.4 ± 4.85 18.6 ± 7.8
IgG2a 31.6 ± 1.2 33.2 ± 3.0
IgG2b 31.4 ± 0.3 29.6 ± 1.4
IgG3 9.2 ± 1.2 16.0 ± 2.1
Rat IgG1 34.2 ± 1.6 29.4 ± 1.6
IgG2a 33.0 ± 0.6 0
IgG2b 31.2 ± 1.6 0
Sample: 1.0 ml sample spiked with 50 μg of antibody.
Beads: 10 μl bead.
Average and standard deviation were calculated from triplicate samples.
Table 3
Dye-to-antibody ratios of mouse IgG2a using thiol chemistry.
Magnetic Protein G beads Magnetic Protein A beads
Antibody
recovery
(μg)
Dye to
antibody
ratio
(DAR)
Antibody
recovery
(μg)
Dye to
antibody
ratio
(DAR)
1 Puriﬁcation 263.7 ± 10.4 0 269.4 ± 5.1 0
2 AlexaFluor532 182.9 ± 15.3 5.3 ± 0.04 189.1 ± 6.9 6.9 ± 0.2
3 AlexaFluor647 192.5 ± 2.9 3.3 ± 0.1 112.3 ± 11.4 3.6 ± 0.2
4 Fluorescein 179.5 ± 5.3 6.8 ± 0.1 201.5 ± 6.5 6.8 ± 0.1
20 μl of bead slurry was used with a 1.0 ml sample and a dye concentration of 67 μmol.
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ies was compared. For this comparison, antibodies from duplicate sam-
ples were captured using 10 μl of Protein G beads, and after washing,
antibodies were eluted from one set of beads to obtain puriﬁed anti-
body. A second set of beads with captured antibodies was used to
label and recover antibodies as described above. The efﬁciency of la-
beled antibody recoverywas calculated by comparing the amount of an-
tibody recovered from two different sets and was 70% for mIg2a and
mIgG2b and 50% for mIgG1 (Table 2). This recovery using on-bead con-
jugation is much higher compared to about 30% reported for the
solution-based conjugation reaction (Acchione et al., 2012). High anti-
body recovery can be attributed to the high afﬁnity between antibody
and Protein G, which is strong enough to withstand multiple reaction
andwashing stepswithout antibody loss. In addition, excellentmagnet-
ic response of themagnetic Protein G beadsminimizes any loss of beads
during puriﬁcation. Furthermore, the conjugated antibodywas eluted in
120 μl, which results in antibody concentration of 200–500 μg/ml com-
pared to 50–100 μg/ml present in the initial sample. It isworthmention-
ing that all of the puriﬁcation and conjugation steps were easily
performed in triplicate and in parallel (n = 18) because of the ease of
handling of magnetic beads.
Since the capture and conjugation of antibody was performed di-
rectly from cell media, it is important to check the purity of the conju-
gated antibody, which was done by resolving the conjugated antibody
on a SDS-PAGE gel. The gel was ﬂuorescently scanned to detect
AlexaFluor 532 conjugated to the antibody heavy and light chains and
then Coomassie stained to test for purity (Fig. 4A). The results indicate
that both the heavy (55 kDa) and the light chains (25 kDa) are ﬂuores-
cently labeled and the conjugated antibodies are pure. Also, no ProteinG
leaching from the beads was observed under the conditions used for
conjugation.Table 2
On-bead antibody conjugation using amine and thiol chemistry.
Amine Reaction
Well Isotype Antibody Recovery (μg) Dye to An
1 Mouse IgG1 Puriﬁcation 54.8 ± 1.8 0
2 Conjugation 27.4 ± 3.2 4.2 ± 0.2
3 Mouse IgG2A Puriﬁcation 85.9 ± 6.4 0
4 Conjugation 60.7 ± 3.2 4.4 ± 0.1
5 Mouse IgG2B Puriﬁcation 79.9 ± 6.9 0
6 Conjugation 66.7 ± 0.5 5.6 ± 0.13.3. Puriﬁcation and on-bead conjugation of mouse antibodies using thiol
reaction
Thiol chemistry is another approach used for attaching small mole-
cules to antibodies (Doronina et al., 2003). Antibodies have intra-chain
disulﬁde bonds as well as inter-chain disulﬁde bonds; however, only
the inter-chain disulﬁde bonds in the antibody hinge region are
solvent-accessible and can be reduced to free thiol groups using reduc-
ing agents like DTT (Dithiothreitol) or TCEP (Tris(2-Carboxyethyl)
phosphine hydrochloride). For on-bead conjugation using thiol chemis-
try, antibodies were captured from the cell culture media as described
previously using 10 μl of beads. Antibodies were reduced using
2.5mMDTT, and after washing to remove DTT, reactedwith AlexaFluor
532 dye containing a thiol-reactive maleimide group (AlexaFluor 532-
ME). Beads were washed to remove excess free ligand and labeled anti-
body eluted and neutralized. DAR of 5.5 was obtained for mIgG2a and
mIgG2b, while mIgG1 had a lower DAR of 1.6. A range of DAR is expect-
ed depending on antibody isotype, conjugation chemistry and the dye.
Further optimization could improve the DAR of speciﬁc antibodies if
needed. Recovery of conjugated antibody was N70% as seen with
amine chemistry, and the eluted antibody was concentrated. Purity of
the antibody and ﬂuorescent labeling of the antibody was conﬁrmed
using SDS-PAGE gel (Fig. 4B) and is similar to that obtained with
amine chemistry.3.4. On-bead conjugation of mouse IgG2a with multiple ﬂuorescent dyes
The studywas further expanded to test the robustness andﬂexibility
of the on-bead conjugation method using (a) two additional thiol reac-
tive dyes, AlexaFluor 647 and Fluorescein, and (b) cell media samples
containing mIgG2a at three- to fourfold higher antibody titer than pre-
viously used. On-bead conjugationwasperformed onboth themagnetic
Protein G and Protein A beads because, even though Protein G haswider
antibody binding speciﬁcity, Protein A is widely used in academic re-
search and the biologics industry. In addition, although both Protein A
and Protein G bind to the Fc region of the antibody, their mechanisms
of binding are different (Sauer-Eriksson et al., 1995). Antibody FcThiol Reaction
tibody Ratio (DAR) Antibody Recovery (μg) Dye to Antibody Ratio (DAR)
49.2 ± 2.0 0
46.2 ± 3.5 1.6 ± 0.2
75.3 ± 8.0 0
61.5 ± 7.4 5.5 ± 0.4
73.3 ± 1.4 0
55.7 ± 0.9 5.2 ± 0.5
Fig. 4.Gel images of antibody (mIgG1,mIgG2a andmIgG2b) coupled using amine (A) or thiol (B) chemistry. Gelswereﬁrst scanned forﬂuorescence to detect AlexaFluor 532 labeled heavy
and light chains and subsequently stained with Coomassie and scanned again. Lanes 1–6 correspond to samples in Table 2.
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with Protein G is ionic and may inﬂuence on-bead conjugation.
Results indicate that on-bead conjugation worked very well for all
three ﬂuorescent dyes with DAR in the range of 3–7 dyes per antibody
(Table 3). Lower DAR for AlexaFluor 647 dye may possibly be due to
its structure, which is based on carbocyanine, whereas AlexaFluor 532
and Fluorescein are rhodamine-based dyes. Overall recoveries of conju-
gated antibodies were around ~70%, except for AlexaFluor 647 conjuga-
tion on magnetic Protein A beads, for which recovery was about 42%. In
addition, no signiﬁcant difference is seen in conjugation performed on
magnetic Protein G and Protein A beads for mIgG2a that binds equally
well to both Protein A and Protein G. However, in cases where antibod-
ies, for example mIgG1, Rat Ig2a and Rat IgG2b, don't bind efﬁciently to
Protein A, use of magnetic Protein G may result in better recoveries.
This study clearly demonstrated that the on-bead conjugationmeth-
od is suitable for combining antibody labeling and puriﬁcation in a sin-
gle step. It was also shown that this method is compatible with labeling
several antibody isotypes present over a range of antibody titers with a
variety of ﬂuorescent dyes.Fig. 5. (A) Gel images of Trastuzumab and Human IgG conjugated to AlexaFluor 647 ﬂuorescen
light chain and subsequently stained with Coomassie and scanned again. (B) ELISA of Trastuzum
MDA-MB-231 cells with low HER2 proteins ﬁxed to the bottom of a 96-well plate was used fo3.5. On-bead conjugation and effect on antibody functionality
After showing the feasibility of on-bead conjugation, it was further
investigated whether on-bead conjugation affected the functionality of
the antibodies. An anti-HER2 antibody (Trastuzumab) was selected as
a proof-of-concept because both the unlabeled antibody (Herceptin)
and antibody labeled with the drug Maytansinoids (Kadcyla) have
been approved by the FDA for cancer treatment (T-DM1) (Burris et al.,
2011) and are known internalizing antibodies. Human IgG was used
as a negative control, and both antibodies were labeled with AlexaFluor
647 using amine chemistry. A DAR of ~3.5 was obtained for each, and
the conjugation of dye to heavy and light chain was conﬁrmed by
using SDS-PAGE gel analysis (Fig. 5A). Two different assays were used
to test the functionality of Trastuzumab.
Theﬁrst assaywas a cell-based sandwich ELISA assay to compare the
binding afﬁnity of unconjugated and AlexaFluor 647-conjugated
Trastuzumab. Results show a similar limit of detection (1.0 ng/ml) for
unconjugated and conjugated Trastuzumab, but a slight decrease in
the afﬁnity of Trastuzumab was observed after dye coupling (Fig. 5B).t dye. The gel was ﬁrst scanned for ﬂuorescence to detect ﬂuorescently labeled heavy and
ab and Trastuzumab conjugated to AlexaFluor 647. HER2 overexpressing SKBR3 cells and
r binding.
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cent molecule is not uncommon especially with lysine chemistry and
has been reported previously (Vira et al., 2010). This loss can be mini-
mized by changing the conjugation chemistry and reaction conditions.
Binding of Trastuzumab to HER2-expressing SKBR3 cells was speciﬁc
as determined by low binding of both conjugated and unconjugated
Trastuzumab to MDA-MB231 cells with very low expression of HER2.
The second assay explored the receptor-mediated internalization of
the Trastuzumab–AlexaFluor 647 conjugate. In this assay, ﬂuorescent
dye-labeled antibodies bind to their speciﬁc receptor expressed on the
cells and upon internalization trafﬁc into endocytic vesicles, which ap-
pear as small ﬂuorescent dots or punctate structures within the cyto-
plasm when seen using microscopy. Trastuzumab–AlexaFluor 647
incubated with HER2-positive SKBR3 cells results in antibody binding
to HER2, which is then slowly internalized over 24 h (Fig. 6A–C)
and can be seen as ﬂuorescent punctate structures within the cells. In-
ternalization is speciﬁc because MDA-MB-231 cells treated with
Trastuzumab–AlexaFluor 647 (Fig. 6E) and SKBR3 cells treated with
human IgG-AlexaFluor 647 do not show any internalization (Fig. 6D).
It is known that conjugating small molecules to the antibody may
impact the antigen-binding afﬁnity of the antibody (Vira et al., 2010;
Lundberg et al., 2007; Shrestha et al., 2012), but the goal is to minimize
the deleterious effect. These results clearly demonstrate that the on-
bead conjugation method has the advantage of being a simple and ro-
bustmethod for labeling antibodieswith a variety of smallmolecules di-
rectly from cell media with no signiﬁcant impact on the antibody
functionality.
4. Discussion
Developing validated labeled antibody requires the ability to pre-
pare and screen a large library of labeled antibodies for desiredFig. 6. Cell internalization of AlexaFluor 647 conjugate of Trastuzumab made using amine ch
AlexaFuor 647 and imaged at (A) 0 h, (B) 3 h and (C) 24 h to monitor internalization. (D) Hu
at 24 h. (E) The MDA-MB-231 cell line expressing very low level of HER2 was incubated withdownstream biological application. Here we present an on-bead conju-
gation method using high-capacity magnetic Protein A and Protein G
beads that enables single-step combined puriﬁcation and conjugation
of antibodies directly from cell media and allows processing of several
samples in parallel. Furthermore, the method is compatible with two
commonly used labeling chemistries and can be used to label various
isotypes of mouse and human antibodies. The labeled antibodies are
functional and can be used directly in the downstream applications re-
quired to characterize antibodies.
For successful implementation of on-bead antibody conjugation
high-capacity antibody-binding Protein G and Protein A magnetic
beads ﬁrst were developed by combining hydrophilic and porous mag-
netic cellulose beads with covalent and oriented attachment using
HaloTag technology. The choice of HaloTag technology was based on
their previous use for protein immobilization (Hoppe et al., 2012;
Wang et al., 2013) and the advantages it offers, including: (1) it allows
the sameHaloTag ligand-activatedmagnetic bead to be used formaking
both Protein A and Protein G beads; (2) the capture of the HaloTag fu-
sion protein is quantitative, which ﬁne tunes the amount of Protein A
and Protein G needed for maximum antibody binding; (3) it allows ro-
bust covalent attachment of Protein A and Protein G, which prevents
leaching as demonstrated by the absence of Protein G in antibody sam-
ples analyzed using SDS-PAGE gel. The observation is similar to another
report, where HaloTag was used to prevent protein losses from surface
under harsh denaturating conditions (Wang et al., 2013); and (4) the
oriented attachment should overcome the limitation of the traditional
random protein immobilization method, which often results in loss of
protein activity and requires time-consuming protein-speciﬁc optimi-
zation (Rusmini et al., 2007; Wilchek and Miron, 2003).
Efﬁcient recovery of antibodies is a key aspect of the antibody puri-
ﬁcation and labeling method and is especially vital when samples con-
tain low amounts of antibody. Thus the performance of on-beademistry. SKBR3 cells overexpressing HER2 were incubated with 30nM of Trastuzumab–
man IgG-AlexaFluor 647 (negative control) was incubated with SKBR3 cells and imaged
Trastuzumab–AlexaFuor 647 and used as an additional negative control.
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conjugationmethods. One of themajor concerns was that on-bead con-
jugation involvesmultiplewashing and incubation steps andmay result
in a signiﬁcant loss of antibody. However, recovery of 50–70% using on-
bead conjugation compare very favorably with the reported solution-
based method of 30–55% (Acchione et al., 2012) and is probably due
to the robust binding between antibody and Protein A and Protein G.
High antibody recovery is especially attractive because it is achieved
with small amounts (50–100 μg) of antibody. In addition to efﬁcient re-
covery, the DARs (1.6–6.9) obtained using on-bead conjugation corre-
late well with the range of 2–4 that has been determined to be
optimum (Hamblett et al., 2004;McDonagh et al., 2006) for therapeutic
ADCs and for maintaining antibody activity (Vira et al., 2010). Further,
the ability to label low-concentration antibody with a therapeutically
relevant DAR of 2–4 using on-bead conjugation is especially useful for
amine-based chemistries because the amine-reactive succinimidyl
ester group is susceptible to hydrolysis in aqueous conditions. To mini-
mize the hydrolysis side reaction, traditional solution-based methods
require a high concentration of puriﬁed antibody (1–10 mg/ml) in
order to drive the reaction towards antibody conjugation (Strachan
et al., 2004).
A possible concern with on-bead conjugation is that binding to Pro-
tein A or Protein G in close proximity of the bead surface may sterically
hinder reactive sites on the antibody. This concern is partially addressed
by the observation that by using thiol chemistry an average DAR of 6.9
for mouse IgG2A out of a maximum of 10 thiols that are solvent-
accessible could be achieved (Lyon et al., 2012). A related concern is
the possibility that distribution of dye on the antibody, especially
using lysine chemistry, may be different than that which results from
solution-based chemistry. However, even with solution-based chemis-
try, distribution of antibodies with different numbers of dyes per anti-
body is a major challenge, and there are concerted efforts to develop
site-speciﬁc conjugation methods (Panowksi et al., 2014; Junutula
et al., 2008; Rabuka et al., 2012; Wu et al., 2009).
Labeled antibodies often need to be dialyzed into buffer that is ap-
propriate for a downstream application, for example ELISA, internaliza-
tion studies, cell toxicity assays and others. However, due to the high
capacity of magnetic beads, small volumes of beads can capture and
concentrate antibody from diluted (0.05–0.1 μg/ml) cell media and
allow elution of conjugated antibody in a small volume at a relatively
high concentration (0.2–0.5 mg/ml). Availability of high-concentration
ﬂuorescent antibodies allowed functional assays such as ELISA and in-
ternalization assays to be run without any additional buffer exchange.
A key parameter for any antibody-labelingmethod is tomaintain the
antigen binding afﬁnity of the conjugated antibody. Using Trastuzumab
as one example it was shown that the on-bead conjugation method
maintained the functionality of the antibody for both binding to its an-
tigen (HER2) in vitro as well as in a cell-based internalization assay. The
small shift in IC50 of labeled Trastuzumab reported for the ELISA assay is
not unexpected especially with amine chemistry since dyes can bind to
lysines present in proximity to antigen binding and thus modify the af-
ﬁnity for antigen binding. Similar observations have been made with
other antibodies used in this manner (Vira et al., 2010).
Several advantages of on-bead antibody puriﬁcation and conjuga-
tion directly from cell media have been highlighted; however, the use
of cell media poses few challenges. One limitation is that the antibody
titer and antibody isotypes in early hybridoma samples may not be
known. As a result, using a single concentration of reactive small mole-
cule may over- or under-label the antibodies. In addition, DARs and an-
tibody recoveries will also vary depending on the antibody titer and
antibody isotypes. Only two different ﬂuorescent dyes were tested;
however, other cytotoxic drugs used in ADCs are hydrophobic and at
high labeling ratios may aggregate or stick to the beads resulting in
lower recoveries. However the solubility problem is not unique to on-
bead conjugation and has been reported for the traditional solution-
based labeling method (Wakankar et al., 2010). This problem can bemitigated by optimizing the elution buffer. Finally, scalability of the con-
jugation method is important as larger scale production of labeled anti-
bodies is required. The on-bead conjugation was scaled to 50 ml of cell
media with similar DAR and antibody recoveries (data not shown), but
at larger scales, the conjugation process will have to be transitioned to
solution-based chemistry and may need re-optimization at various
steps. Notwithstanding these limitations, on-bead conjugation is an en-
abling approach for primary screening of antibody and label together in
the context of the desired biological application and should allow selec-
tion of well characterized antibody reagents.5. Conclusions
In conclusion we have developed an on-bead antibody-small mole-
cule conjugation process using high-capacity magnetic Protein G and
Protein A beads that may simplify the process of selecting high-quality
validated labeled antibody reagents. Key highlights of this method are
(a) antibody present in the cell media can be conjugated without prior
puriﬁcation, (b) small volumes of cell media samples (1 ml) containing
low amount of antibodies (50 μg/ml) can be labeled, (c) multiple anti-
body samples can be labeled in parallel, (d) conjugated antibodies are
functional and (e) labeled antibodies are eluted at high concentration
suitable for a variety of downstream applications. Finally, given the ad-
vantages of the on-bead conjugation method, it is easy to imagine that
this approach can be extended to other areas of biological research
that use antibodies labeled with small molecules, proteins, enzymes,
polymer and nanoparticles among others.References
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